Eugit Therapeutics
Enabling Tissue Targeting of Therapies
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator (S22). Eugit Therapeutics is a Y Combinator company (Summer 2022). YC-listed status: Active.
- Website
- eugittx.com
- Location
- San Francisco, CA, USA; South San Francisco, CA, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Eugit Therapeutics — Tissue-targeting drug delivery platform using T cell receptors to treat inflammatory diseases with precision. · Other
Links
- Y Combinator profileycombinator